Rehabilitation Unit, University of Miyazaki Hospital, 5200 Kihara Kiyotake Miyazaki, Miyazaki, 889-1692, Japan.
School of Nursing, Faculty of Medicine, University of Miyazaki, 5200 Kihara Kiyotake Miyazaki, Miyazaki, 889-1692, Japan.
J Orthop Sci. 2022 Mar;27(2):408-413. doi: 10.1016/j.jos.2020.12.028. Epub 2021 Feb 25.
In 2020, the Japanese Orthopaedic Association established a new stage 3 in clinical decision limits (CDL) to evaluate the stage of locomotive syndrome (LS). This study focused on total CDL stage 3 with the aim of investigating indicators related to improvements in total CDL by evaluating the improvement of LS in patients who underwent total hip arthroplasty (THA).
Of the 125 patients who underwent THA at our hospital, the subjects of the analysis were 105 patients determined to be total CDL stage 3 in an evaluation performed before THA. LS was evaluated using the stand-up test, two-step test, and 25-Question Geriatric Locomotive Function Scale (GLFS-25). Indicators related to improvements in total CDL were also investigated. All evaluation items were measured before THA and three months after THA.
Before THA, all subjects (n = 105) were classified as total CDL stage 3. Three months after THA, improvements in total CDL were seen in 49 subjects (46.7%). The results of stepwise multiple logistic regression analysis showed that the before THA stand-up test and GLFS-25 were significantly related to improvements in total CDL.
Three months after THA, improvements in LS were seen in approximately half of the subjects. The stand-up test and GLFS-25 can be used as indicators of improvement in total CDL.
Prospective cohort study design.
2020 年,日本矫形外科学会制定了新的临床决策界限(CDL)第 3 阶段,用于评估运动综合征(LS)的阶段。本研究重点关注总 CDL 第 3 阶段,旨在通过评估接受全髋关节置换术(THA)的患者 LS 的改善,研究与总 CDL 改善相关的指标。
在我院接受 THA 的 125 例患者中,分析对象为术前评估确定为总 CDL 第 3 阶段的 105 例患者。使用站立试验、两步试验和 25 问老年运动功能量表(GLFS-25)评估 LS。还研究了与总 CDL 改善相关的指标。所有评估项目均在 THA 前和 THA 后 3 个月进行测量。
THA 前,所有患者(n=105)均被归类为总 CDL 第 3 阶段。THA 后 3 个月,49 例患者(46.7%)总 CDL 改善。逐步多因素逻辑回归分析结果显示,THA 前站立试验和 GLFS-25 与总 CDL 的改善显著相关。
THA 后 3 个月,约一半患者 LS 改善。站立试验和 GLFS-25 可作为总 CDL 改善的指标。
前瞻性队列研究设计。